AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03427359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, capecitabine
Description: Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
Study NCT03725189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG during exercise
Description: PPG use for pulse waveform evaluation of healthy exercise group
Study NCT00003120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 135 mg/m2 IV every 28 days
Study NCT00003120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 135 mg/m2 IV every 28 days
Study NCT04220294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous tissue closure
Description: Subcutaneous tissue closure with 2-0 vicryl suture.
Study NCT04421911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen topical
Description: Ketoprofen topical for 21days
Study NCT04421911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Topical
Description: Diclofenac topical for 21days
Study NCT05066516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCDP, dapagliflozin 10mg/linagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin
Description: FCDP, dapagliflozin 10mg/linagliptin 5 mg or ICs, co-administration of a single dose of dapagliflozin and linagliptin
Study NCT03229265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
Study NCT02850458 — intervention group
Intervention type: DEVICE
Intervention: implant-retained overdentures
Description: patients treated with an implant-retained overdenture in the mandible
Study NCT02261636 — intervention group
Intervention type: DRUG
Intervention: mesalazine
Study NCT00149916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (enteric coated)
Study NCT01063764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted.
Study NCT03244865 — intervention group
Intervention type: DEVICE
Intervention: LaborView Electronic Fetal Monitor
Description: Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus.
Study NCT03898349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system
Description: Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
Study NCT03898349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system with Usual implementation
Description: Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls
Study NCT03898349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annie text messaging system with Augmented implementation
Description: Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance
Study NCT04371445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic Insert
Description: DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
Study NCT02477501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: continuous infusion
Study NCT02477501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: continuous infusion
Study NCT03476083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
Description: All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
Study NCT03476083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.
Description: All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
Study NCT02029651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-glove system
Description: Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
Study NCT02029651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy
Description: conventional occupational therapy
Study NCT03647540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescent laparoscopic radical gastrectomy
Description: The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
Study NCT03647540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic radical gastrectomy
Description: The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
Study NCT03095066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules
Study NCT03095066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as capsules
Study NCT03095066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-28
Description: 28 mg of d6-DM and 4.9 mg of Q
Study NCT03095066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786-42.63
Description: 42.63 mg of d6-DM and 4.9 mg of Q
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Participants will consume 30 kcal/kg FFM/day.
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Participants will consume 30 kcal/kg FFM/day.
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will consume 1.7 g protein/kg BW/day.
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Participants will consume 1.7 g protein/kg BW/day.
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
Study NCT02945410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
Study NCT02945410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
Study NCT02945410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
Study NCT02945410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
Study NCT02848677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
Study NCT02848677 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: usual care of hypertensive patients.
Study NCT04371445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
Study NCT02134132 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Gel
Description: Application of platelet gel in patients suffering from diabetic foot ulcers.
Study NCT02134132 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
Study NCT03780842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA level
Description: A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV.
Study NCT01856790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT01856790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist
Study NCT04133493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kerecis Omega3 Wound
Description: The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week.
Study NCT04133493 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fibracol
Description: The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
Study NCT03284762 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
Study NCT00773994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal Velopharyngeal Mechansim
Description: The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
Study NCT00733109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of the lesion
Description: Surgery with Large Loop Excision of Transformation Zone (LLETZ)
Study NCT03943524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interax-AI
Description: Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
Study NCT02049385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: A nondiuretic vasodilator thiazide-related agent
Study NCT02049385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04189198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Supraclavicular block with 30 ml articaine 2%
Study NCT04189198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Supraclavicular block with 30 ml bupivacaine 0.5%
Study NCT01003691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
Study NCT01003691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous, multiple dose with experimental dose
Study NCT02887508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HINTS Intervention
Description: HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
Study NCT02887508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
Study NCT04480905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic tape
Description: The dynamic tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
Study NCT00733109 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Follow-up for spontaneous regression of the lesion
Description: Follow-up at last 12 months
Study NCT01661712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
Study NCT01661712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation for one night (no electrical stimulation)
Study NCT03314727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High salt (NaCl) intake
Description: Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
Study NCT02596854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurological MRI
Description: Neurological MRI image collection
Study NCT04400396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: standard HM fortification
Description: Based on the assumed energy and macronutrient composition of HM, the commercial multi-component HM fortifier was added, in order to compensate identified nutritional deficits.
Study NCT04400396 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: target HM fortification
Description: Based on the measured energy and macronutrient composition of HM, modular protein and fat supplements are added, in addition to the commercial multi-component HM fortifier, in order to correct identified specific nutritional deficits. For this purpose, an Excel program to calculate modular protein and fat supplements to be added to fortified HM was developed and registered (Nona R, Cardoso M, Portuguese Directorate of Intellectual Property Services, IGAC-DSPI, nº 480/2020, 26 February 2020)
Study NCT02750891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888
Description: Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
Study NCT04480905 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tape
Description: The 3M™ Soft Cloth Tape will stick from anterior inferior iliac spine to the middle of the tibia in supine and full knee extension position
Study NCT01745159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT01843387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single Intravenous Infusion of MPCs Dose 1 or Placebo
Study NCT01843387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single Intravenous Infusion of MPCs Dose 2 or Placebo
Study NCT02946996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04102917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QFR assessment
Description: The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
Study NCT03196843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
Study NCT03196843 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiotherapy
Description: Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
Study NCT03196843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
Study NCT02449980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Surgery Group
Description: Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
Study NCT02449980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial Non-operative management
Description: Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
Study NCT02946996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPC
Description: OPC is a derivative of grape seed extract
Study NCT02230501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stringent diet regimen
Study NCT02230501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate diet regimen
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/placebo/pioglitazone
Description: single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
Study NCT02114346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin